Filing Overview
Filing: Form 10-K for the fiscal year ended December 31, 2015, filed March 30, 2016. The provided filing identifies the registrant as Zeta Acquisition Corp. II, not Whitehawk Therapeutics, Inc.; investors should verify the company identity and filing metadata.
Business Context
Zeta Acquisition Corp. II is a Delaware blank-check and shell company formed to identify and complete a business combination. It had not identified a target, entered into negotiations, or conducted operating activities as of the filing date. The company had no employees other than its officers and directors, no owned or leased property, and no publicly traded market for its common stock.
Financial Metrics
| Metric | 2015 | 2014 |
|---|---|---|
| Revenue | $0 | $0 |
| Net loss | $(31,440) | $(30,799) |
| General and administrative expense | $23,006 | $23,972 |
| Interest expense | $8,434 | $6,827 |
| Cash and cash equivalents | $18,529 | $5,263 |
| Total liabilities | $205,010 | $160,304 |
| Stockholders’ deficit | $(186,481) | $(155,041) |
| Net cash used in operating activities | $(21,734) | $(16,020) |
| Net cash provided by financing activities | $35,000 | $15,000 |
Because the company generated no revenue, gross or operating margins are not meaningful. Cash increased by $13,266 during 2015, primarily because stockholders provided $35,000 of financing, offset by $21,734 of operating cash use. Notes payable to stockholders totaled $160,000 at year-end, were unsecured, bore interest at 6%, and were due on demand. Accrued and unpaid interest was $32,436.
Material Changes Versus 2014
- Net loss increased modestly by $641, or approximately 2%.
- Operating cash use increased by $5,714, or approximately 36%.
- Cash increased by $13,266, compared with a $1,020 decrease in 2014, due to higher stockholder financing.
- Total liabilities increased by $44,706, principally reflecting an increase in stockholder notes payable from $125,000 to $160,000 and higher accrued interest.
- Stockholders’ deficit increased from $(155,041) to $(186,481).
- The company issued no equity securities during the quarter ended December 31, 2015, and continued to have 5,000,000 common shares outstanding.
Outlook, Risks, and Unusual Items
Management planned to continue searching for a suitable business combination, but reported no identified target or definitive agreement. The company expects to fund reporting, acquisition-search, and transaction costs through existing cash, deferred service-provider fees, additional stockholder or management loans, or equity financing associated with a reverse merger. No assurance was provided that additional financing would be available.
Management and the auditor identified substantial going-concern uncertainty. The company has generated no revenue since inception, depends on related-party funding, has nominal assets relative to liabilities, and cannot assure that it can satisfy cash requirements for the next twelve months. Its ability to continue depends on obtaining financing and completing a suitable business combination.
Additional risks include limited management time and resources, potentially inadequate due diligence, intense competition for acquisition targets, significant dilution in a transaction, lack of diversification, the possibility of acquiring an early-stage or financially unstable business, and the potential loss of transaction-related costs if a proposed combination is not completed. The company had no material pending legal proceedings and no material off-balance-sheet arrangements.
Stockholder loans were the principal related-party financing source. Officers and directors received no compensation, and the company used management office space and equipment at no cost. A full valuation allowance was recorded against deferred tax assets; no income tax benefit was recognized.
Important Facts to Verify
- Confirm that this filing belongs to Zeta Acquisition Corp. II rather than Whitehawk Therapeutics, Inc.
- Verify the company’s ability to obtain additional financing and the payment terms or potential demands on the $160,000 of stockholder notes.
- Assess the going-concern disclosure, including the absence of revenue and reliance on related parties.
- Determine whether any business combination, reverse merger, or change in control occurred after December 31, 2015.
- Evaluate potential dilution from any future acquisition financing or issuance of securities.
- Review ownership concentration: officers and directors collectively held 80% of the outstanding common stock as of March 30, 2016.
- Confirm that the audited financial statements and auditor’s opinion relate to the same registrant identified in the filing.